German industry wants say in reimbursement decisions:
This article was originally published in Clinica
Executive Summary
Germany's BVMed industry association says its knowledge and expertise should be used by the health ministry's reimbursement bodies when it comes to decision-making on healthcare products. In a recent position paper (see www.bvmed and go to Publikationen- Stellungnahme), the Berlin association said its practical, industry-relevant insight would be valuable to the joint federal committee (G-BA) and its executive arm, IQWiG in bringing cost-effective, innovative advanced medical technologies into circulation. BVMed director Joachim Schmitt has long campaigned for industry to be better consulted on technical medtech issues, on cost-benefit grounds and for the benefit of German patients (see Clinica No 1157, p 8).
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.